Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prosensa Holding BV

Division of BioMarin Pharmaceutical Inc.
www.prosensa.eu

Latest From Prosensa Holding BV

Interview: Mallinckrodt Deal Golden For Silence Therapeutics

The gene silencing specialist has signed a collaboration that CEO David Horn Solomon tells Scrip will help push Silence up among its peers in the RNAi space.

Companies Deals

Real-World Data Boost Santhera's Latest DMD Filing, And The Markets Agree

Despite being knocked back twice, Santhera CEO Thomas Meier is still confident Raxone has a place as a Duchenne muscular dystrophy therapy, and believes new long-term data will strengthen its third application to the EU in the coming months.

Rare Diseases Clinical Trials

FDA’s DMD Decisions: Glass Two-Thirds Full?

The outcome of an US advisory committee review of PTC’s ataluren was not surprising. That is bad news for PTC’s prospects of launching the drug in the near term – but given the recent history of the DMD class, it is probably good news for biopharma companies overall as a sign that FDA's neurology group is moving forward effectively.

Advisory Committees Drug Approval Standards

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.

Rare Diseases Innovation
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Prosensa BV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • BioMarin Pharmaceutical Inc.
  • Senior Management
  • Hans Schikan, CEO
    Berndt Modig, CFO
    Luc Dochez, CBO and SVP, Bus. Dev.
    Giles Campion, MD, CMO and SVP, R&D
    Willem W van Weperen, Chief Commercial Officer
  • Contact Info
  • Prosensa Holding BV
    Phone: (31) 71 3322100
    J.H. Oortweg 21
    Leiden, 2333 CH
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register